HomeAboutEfficacyEfficacyEfficacyTrial DesignSafetySafetyImportant Safety InformationSafety & TolerabilityDosingDosingDosing InformationDose AdjustmentsDrug InteractionsMedical InformationVisit the Pfizer Medical Information Africa Website for Healthcare ProfessionalsSubmit a medical question to Pfizer
Dose Adjustments1Dosing adjustments for renal impairment
In patients with moderate renal impairment, the dose of Nirmatrelvir/Ritonavir Pfizer should be reduced to nirmatrelvir/ritonavir 150 mg/100 mg (1 tablet of each) twice daily for 5 days.
Nirmatrelvir/Ritonavir Pfizer recommended dosage for 5 consecutive days in moderate renal impairment1Morning Dose
One pink 150-mg tablets of nirmatrelvir
One white 100-mg tablet of ritonavir
Patients should take both tablets together.
Evening Dose
One pink 150-mg tablets of nirmatrelvir
One white 100-mg tablet of ritonavir
Patients should take both tablets together.
No dose adjustment of Nirmatrelvir/ ritonavir Pfizer is required for patients with mild renal impairment (eGFR ≥60 to <90 mL/min)1
Nirmatrelvir/ ritonavir Pfizer is not recommended in patients with severe renal impairment (eGFR <30 mL/min)
Dosing adjustments for hepatic impairment1
No dose adjustment of Nirmatrelvir/ ritonavir Pfizer is required for patients with either mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment1
Nirmatrelvir/ ritonavir Pfizer is not recommended in patients with severe hepatic impairment
EXPLORE MOREEfficacy & trial design
Discover the efficacy data and trial design of EPIC-HR.
Contact: KENYA OFFICE: Pfizer Laboratories (Pty) Ltd Vienna Court, First Floor West Wing, State House Crescent, State House Road, Nairobi Kenya, PO Box 18244-00500.
Tel: +254(0)5134110.
This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.
You are now leaving Accord Portal to access Pfizer Medical Information Portal You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.